290 related articles for article (PubMed ID: 28393474)
1. Application of induced pluripotent stem cells to understand neurobiological basis of bipolar disorder and schizophrenia.
Liu YN; Lu SY; Yao J
Psychiatry Clin Neurosci; 2017 Sep; 71(9):579-599. PubMed ID: 28393474
[TBL] [Abstract][Full Text] [Related]
2. Disease signatures for schizophrenia and bipolar disorder using patient-derived induced pluripotent stem cells.
Watmuff B; Berkovitch SS; Huang JH; Iaconelli J; Toffel S; Karmacharya R
Mol Cell Neurosci; 2016 Jun; 73():96-103. PubMed ID: 26777134
[TBL] [Abstract][Full Text] [Related]
3. A dangerous method? The use of induced pluripotent stem cells as a model for schizophrenia.
Jacobs BM
Schizophr Res; 2015 Oct; 168(1-2):563-8. PubMed ID: 26194993
[TBL] [Abstract][Full Text] [Related]
4. Unraveling the biology of bipolar disorder using induced pluripotent stem-derived neurons.
Miller ND; Kelsoe JR
Bipolar Disord; 2017 Nov; 19(7):544-551. PubMed ID: 29116664
[TBL] [Abstract][Full Text] [Related]
5. Stem cell-derived neurons in the development of targeted treatment for schizophrenia and bipolar disorder.
Watmuff B; Liu B; Karmacharya R
Pharmacogenomics; 2017 Apr; 18(5):471-479. PubMed ID: 28346060
[TBL] [Abstract][Full Text] [Related]
6. Understanding neurodevelopmental disorders using human pluripotent stem cell-derived neurons.
Tamburini C; Li M
Brain Pathol; 2017 Jul; 27(4):508-517. PubMed ID: 28585386
[TBL] [Abstract][Full Text] [Related]
7. Advances in the understanding of the pathophysiology of schizophrenia and bipolar disorder through induced pluripotent stem cell models.
Perrottelli A; Marzocchi FF; Caporusso E; Giordano GM; Giuliani L; Melillo A; Pezzella P; Bucci P; Mucci A; Galderisi S
J Psychiatry Neurosci; 2024; 49(2):E109-E125. PubMed ID: 38490647
[TBL] [Abstract][Full Text] [Related]
8. Modeling of psychiatric disorders using induced pluripotent stem cell-related technologies.
Nakazawa T; Hashimoto R; Takuma K; Hashimoto H
J Pharmacol Sci; 2019 Aug; 140(4):321-324. PubMed ID: 31257060
[TBL] [Abstract][Full Text] [Related]
9. Modeling developmental neuropsychiatric disorders with iPSC technology: challenges and opportunities.
Young-Pearse TL; Morrow EM
Curr Opin Neurobiol; 2016 Feb; 36():66-73. PubMed ID: 26517284
[TBL] [Abstract][Full Text] [Related]
10. Modeling Psychiatric Diseases with Induced Pluripotent Stem Cells.
van Hugte E; Nadif Kasri N
Adv Exp Med Biol; 2019; 1192():297-312. PubMed ID: 31705501
[TBL] [Abstract][Full Text] [Related]
11. Using human stem cells as a model system to understand the neural mechanisms of alcohol use disorders: Current status and outlook.
Scarnati MS; Halikere A; Pang ZP
Alcohol; 2019 Feb; 74():83-93. PubMed ID: 30087005
[TBL] [Abstract][Full Text] [Related]
12. Using iPSC Models to Understand the Role of Estrogen in Neuron-Glia Interactions in Schizophrenia and Bipolar Disorder.
Reis de Assis D; Szabo A; Requena Osete J; Puppo F; O'Connell KS; A Akkouh I; Hughes T; Frei E; A Andreassen O; Djurovic S
Cells; 2021 Jan; 10(2):. PubMed ID: 33494281
[TBL] [Abstract][Full Text] [Related]
13. Pluripotent stem cells in neuropsychiatric disorders.
Soliman MA; Aboharb F; Zeltner N; Studer L
Mol Psychiatry; 2017 Sep; 22(9):1241-1249. PubMed ID: 28322279
[TBL] [Abstract][Full Text] [Related]
14. Neurodevelopmental origins of bipolar disorder: iPSC models.
O'Shea KS; McInnis MG
Mol Cell Neurosci; 2016 Jun; 73():63-83. PubMed ID: 26608002
[TBL] [Abstract][Full Text] [Related]
15. The application of human pluripotent stem cells to model the neuronal and glial components of neurodevelopmental disorders.
Lee KM; Hawi ZH; Parkington HC; Parish CL; Kumar PV; Polo JM; Bellgrove MA; Tong J
Mol Psychiatry; 2020 Feb; 25(2):368-378. PubMed ID: 31455859
[TBL] [Abstract][Full Text] [Related]
16. Characterization of bipolar disorder patient-specific induced pluripotent stem cells from a family reveals neurodevelopmental and mRNA expression abnormalities.
Madison JM; Zhou F; Nigam A; Hussain A; Barker DD; Nehme R; van der Ven K; Hsu J; Wolf P; Fleishman M; O'Dushlaine C; Rose S; Chambert K; Lau FH; Ahfeldt T; Rueckert EH; Sheridan SD; Fass DM; Nemesh J; Mullen TE; Daheron L; McCarroll S; Sklar P; Perlis RH; Haggarty SJ
Mol Psychiatry; 2015 Jun; 20(6):703-17. PubMed ID: 25733313
[TBL] [Abstract][Full Text] [Related]
17. Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models.
Haggarty SJ; Silva MC; Cross A; Brandon NJ; Perlis RH
Mol Cell Neurosci; 2016 Jun; 73():104-15. PubMed ID: 26826498
[TBL] [Abstract][Full Text] [Related]
18. Transcriptomics analysis of iPSC-derived neurons and modeling of neuropsychiatric disorders.
Lin M; Lachman HM; Zheng D
Mol Cell Neurosci; 2016 Jun; 73():32-42. PubMed ID: 26631648
[TBL] [Abstract][Full Text] [Related]
19. Early onset of inflammation during ontogeny of bipolar disorder: the NLRP2 inflammasome gene distinctly differentiates between patients and healthy controls in the transition between iPS cell and neural stem cell stages.
Vizlin-Hodzic D; Zhai Q; Illes S; Södersten K; Truvé K; Parris TZ; Sobhan PK; Salmela S; Kosalai ST; Kanduri C; Strandberg J; Seth H; Bontell TO; Hanse E; Ågren H; Funa K
Transl Psychiatry; 2017 Jan; 7(1):e1010. PubMed ID: 28117838
[TBL] [Abstract][Full Text] [Related]
20. Pluripotent stem cells as a model to study oxygen metabolism in neurogenesis and neurodevelopmental disorders.
Paulsen Bda S; da Silveira MS; Galina A; Rehen SK
Arch Biochem Biophys; 2013 Jun; 534(1-2):3-10. PubMed ID: 23111185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
